Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study BioSpace Source link
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced BioSpace Source link
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis Clinical Trials Arena Source link
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I Genetic Engineering and Biotechnology News Source link